Calendar of Events

Foundation Medicine will be attending or presenting data at the following events:

Upcoming Events

Past Events

  • February 25-27, 2013Citi 2013 Global Healthcare Conference, New York City, NY
  • March 14-17, 2012 National Comprehenisive Cancer Network 17th Annual Conference, Hollywood, FL
  • March 7, 2012 Cowen and Company 32nd Annual Health Care Conference, Boston MA
  • Michael J. Pellini, M.D., president and CEO to present at 12:00pm on Tuesday, March 7, 2012
  • February 15-18, 2012 Advances in Genome Biology and Technology (AGBT) Meeting, Marco Island, FL
  • Foundation Medicine to exhibit five posters during various sessions throughout the meeting.
  • January 23-24, 2012 Personalized Medicine World Conference, Mountain View, CA
  • Michael J. Pellini, M.D., president and CEO to present in the Emerging Technologies track on Monday, Jan. 23, 2012 at 10:00am PT
  • January 9-12, 2012 J.P. Morgan 30th Annual Healthcare Conference, San Francisco, CA
  • November 15, 2011 Lazard Capital Markets 8th Annual Healthcare Conference, New York, NY
  • Michael J. Pellini, M.D., president and CEO. to present at Lazard Capital Markets 8th Annual Healthcare Conference on November 15th, 2011, at 2:30pm.
  • November 18, 2011 Association for Molecular Pathology 2011 Annual Meeting, Grapevine, TX

    Foundation Medicine to present poster entitled “Comprehensive Next Generation Sequencing From Formalin Fixed Tissue Representing a Range of Specimen Ages and Tissue Types” in the Friday afternoon Poster Session, Nov.18, 2:15pm – 3:30pm

  • October 24, 2011 BioNetwork West, 2011, Laguna Niguel, CA

    Michael J. Pellini, M.D., president and CEO participated in a panel entitled “Personalized Medicine – Is the Vision Realizable?” at 8:45am

  • October 17, 2011 AACR: Translation of the Cancer Genome: Scientific, Clinical, and Operational Challenges, San Francisco, CA

    Oral Presentation on “Next-generation diagnostics: Expanding clinical actionability of the cancer genome” in Session 7: Defining the Clinical Path Hypothesis Session scheduled for Monday, October 17 from 3:30-5:00 p.m.

  • September 25, 2011 The European Multidisciplinary Cancer Congress (ESMO), Stockholm, Sweden

    Oral presentation in the session "Personalized medicine"

  • July 26, 2011 American Association for Clinical Chemistry (AACC) Annual Meeting 2011, Atlanta, GA

    Poster presentation entitled “Exploratory study using comprehensive next-generation sequencing on DNA from FFPE tumor tissue comparing KRAS, EGFR and BRAF gene mutation results with reference laboratory genotyping assays”

  • July 15-16, 2011 HiTSeq 2011 Conference on High Throughput Sequencing Analysis and Algorithms, Vienna, Austria

    Oral presentation and poster presentation on “An assembly-based algorithm for sensitive detection of insertions and deletions in targeted resequencing data of clinical cancer specimens”

  • July 6, 2011 The 3rd Worldwide Innovative Networking (WIN) Symposium in Personalized Cancer Medicine, Paris, France

    Poster presentation on “Comprehensive mutation profiling by deep sequencing from fixed cancer tissues”

  • June 22 and 24, 2011 Keystone Symposia Conference: Changing Landscape of the Cancer Genome, Boston, MA

    Poster presentation entitled “Applying NGS to cancer genomics for clinical decision making” followed by a talk with the same title

  • June 6, 2011 ASCO 2011 Annual Meeting, Chicago, IL

    Poster presentation on “Comprehensive next-generation sequencing for clinically actionable mutations from formalin-fixed cancer tissues”

  • April 2, 2011 American Association for Cancer Research (AACR) 102nd Annual Meeting 2011, Orlando, FL

    Presentation on “Novel insights into cancer development and progression revealed by whole genome structural variation characterization” during the session “Understanding the Tumor Genome Through Next-Generation Sequencing”

  • March 26, 2011 RECOMB 2011, Vancouver, British Columbia

    Presentation on “A Bayesian approach for sensitive detection of somatic mutations from next-generation sequencing of clinical cancer specimens”